Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
Université de Montréal
$27,000.00
Harnessing Therapy-Induced Senescence to enhance immune antitumor responses
EF 2025-26
Résumé
Metastatic melanoma and ovarian cancer are resistant to standard treatments like chemotherapy and radiotherapy, which trigger therapy-induced cell fate decisions (TICFD) including cell death or senescence and its associated inflammatory secretome (SASP). As these cancers also have suboptimal responses to immunotherapy, it is crucial to understand how the tumor microenvironment (TME) and therapy-induced senescence (TIS) could modulate immune cells anti-tumor response to help develop novel treatments.
We have found that melanoma cells exhibit senescence features in vitro in response to treatments. T cells in contact with these cells develop markers of activation, which suggests that senescent melanoma cells can interfere with T cell functions. Similarly, we have established that ovarian cancer cells undergo senescence in response to chemotherapy. With diverse molecular and cell biology methods as well as cocultures, we will assess the impact of cancer cell fate as well as the impact of SASP on immune cells reactivity and their functions. We will also quantitatively measure the impact of cancer cell fate on immune cells-mediated killing of cancer cells. We expect that TICFD, SASP and the interaction of immune cells between themselves will trigger differential expression profile and secretion. Similarly, we expect that immune cells killing rate and kinetics will depend on tumor cells fate state and microenvironment. We should identify diverse molecular components that may facilitate the understanding of TME-modulated immune anti-tumor response in melanoma/ovarian cancer. Understanding the relationship between TIS and immune cells antitumor response will contribute to determine novel immunotherapy strategies for patients with refractory melanoma or ovarian cancer.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572837
Name
Lacasse Mérédith
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing Therapy-Induced Senescence to enhance immune antitumor responses
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer De L'Ovaire Séreux De Haut Grade; Cellules Immunitaires; Mélanome; Sénescence
Abstract
Metastatic melanoma and ovarian cancer are resistant to standard treatments like chemotherapy and radiotherapy, which trigger therapy-induced cell fate decisions (TICFD) including cell death or senescence and its associated inflammatory secretome (SASP). As these cancers also have suboptimal responses to immunotherapy, it is crucial to understand how the tumor microenvironment (TME) and therapy-induced senescence (TIS) could modulate immune cells anti-tumor response to help develop novel treatments.
We have found that melanoma cells exhibit senescence features in vitro in response to treatments. T cells in contact with these cells develop markers of activation, which suggests that senescent melanoma cells can interfere with T cell functions. Similarly, we have established that ovarian cancer cells undergo senescence in response to chemotherapy. With diverse molecular and cell biology methods as well as cocultures, we will assess the impact of cancer cell fate as well as the impact of SASP on immune cells reactivity and their functions. We will also quantitatively measure the impact of cancer cell fate on immune cells-mediated killing of cancer cells. We expect that TICFD, SASP and the interaction of immune cells between themselves will trigger differential expression profile and secretion. Similarly, we expect that immune cells killing rate and kinetics will depend on tumor cells fate state and microenvironment. We should identify diverse molecular components that may facilitate the understanding of TME-modulated immune anti-tumor response in melanoma/ovarian cancer. Understanding the relationship between TIS and immune cells antitumor response will contribute to determine novel immunotherapy strategies for patients with refractory melanoma or ovarian cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lacasse, Mérédith
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~